# Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Study · id `cardio:ct-nct07263308` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07263308](<https://clinicaltrials.gov/study/NCT07263308>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07263308

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1192 participants.

## Technical summary

Registry record NCT07263308. Randomized; no masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2027-06-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1192 participants (planned count; ClinicalTrials.gov record NCT07263308, source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)
- Started: 2025-12-18 (actual) (ClinicalTrials.gov record NCT07263308, source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2027-06-20 (anticipated) (ClinicalTrials.gov record NCT07263308, source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)
- Completion: 2027-12-01 (anticipated) (ClinicalTrials.gov record NCT07263308, source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07263308, source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07263308-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
- Acronym: ARISE-2
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Albumin
- Intervention (Procedure): Endovascular treatment
- Lead sponsor: Capital Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Capital Medical University (`cardio:org-capital-medical-university`)

## Provenance

Content hash: d6a29c9ba2d5590f01e8d940a03e77f03399aa3c9871b7262a527011af3423d4
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
